Market Newsdesk

Wales to Host United Kingdom’s First Major WWE® Stadium Event in 30 Years at Cardiff’s Principality Stadium

 Premium Live Event will take place on Saturday, September 3, 2022

STAMFORD, Conn.–(BUSINESS WIRE)–
WWE (NYSE: WWE) today announced that the first major WWE stadium event to be held in the United Kingdom in more than 30 years will emanate from Principality Stadium in Cardiff, Wales, on Saturday, September 3, 2022.

Located in the heart of Cardiff, the capital of Wales – a cultural and sports destination with a world class record in hosting events – the Principality Stadium is a state-of-the-art, multi-faceted event destination and home to the Wales national rugby union team.

Fans interested in an exclusive presale opportunity can register at https://wwe.com/cardiff-2022-presale.

“Principality Stadium is the perfect place for a major event, hosting our amazing fans from Wales, throughout all of Europe, and around the world,” said John Porco, WWE Senior Vice President, Live Events. “The weekend will be filled with a variety of WWE experiences that we believe will leave a lasting memory, on par with SummerSlam at Wembley Stadium in 1992.”

“Wales will provide an iconic location for WWE’s return to the UK after 30 years and showcase our country to a global audience of millions, including extended reach in the USA,” said Welsh Government Minister for Economy Vaughan Gething. “This is set to be the perfect addition to a huge year of sport, entertainment and culture in Wales that will attract people from across the globe to experience what our country has to offer.”

“We’re extremely proud that Principality Stadium has been chosen by WWE to host this major event, which is testament to the stadium’s reputation as a world class venue,” said Mark Williams, Principality Stadium Manager. “Principality Stadium is unique in its position at the heart of the city centre, which will undoubtably offer WWE fans an unrivalled event experience both inside and outside of the stadium and bring great benefit to the wider city of Cardiff.”

Information regarding event name, ticket on sale and further event updates will be available soon.

About WWE

WWE, a publicly traded company (NYSE: WWE), is an integrated media organization and recognized leader in global entertainment. The Company consists of a portfolio of businesses that create and deliver original content 52 weeks a year to a global audience. WWE is committed to family-friendly entertainment on its television programming, premium live event, digital media and publishing platforms. WWE’s TV-PG programming can be seen in more than 1 billion homes worldwide in 30 languages through world-class distribution partners including NBCUniversal, FOX Sports, BT Sport, Sony India and Rogers. The award-winning WWE Network includes all premium live events, scheduled programming and a massive video-on-demand library and is currently available in more than 180 countries. In the United States, NBCUniversal’s streaming service, Peacock, is the exclusive home to WWE Network. Additional information on WWE can be found at wwe.com and corporate.wwe.com.

About Event Wales and Welsh Government

This major WWE stadium event is to be hosted in Cardiff, Wales, with support from Welsh Government, delivered in line with its Major Events Strategy. Event Wales work closely with local partners including the Cardiff Council Events Team to attract a range of sporting, cultural and business events to Wales, including spectacular global events such as this, which raise Wales’ profile world-wide and further cement Wales’s reputation as a world-class events destination.

Trademarks: All WWE programming, talent names, images, likenesses, slogans, wrestling moves, trademarks, logos and copyrights are the exclusive property of WWE and its subsidiaries. All other trademarks, logos and copyrights are the property of their respective owners.

Forward-Looking Statements: This press release contains forward-looking statements pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995, which are subject to various risks and uncertainties. These risks and uncertainties include, without limitation, risks relating to: the impact of the COVID-19 outbreak on our business, results of operations and financial condition; entering, maintaining and renewing major distribution agreements; a rapidly evolving media landscape; WWE Network (including the risk that we are unable to attract, retain and renew subscribers); our need to continue to develop creative and entertaining programs and events; the possibility of a decline in the popularity of our brand of sports entertainment; the continued importance of key performers and the services of Vincent K. McMahon; possible adverse changes in the regulatory atmosphere and related private sector initiatives; the highly competitive, rapidly changing and increasingly fragmented nature of the markets in which we operate and greater financial resources or marketplace presence of many of our competitors; uncertainties associated with international markets including possible disruptions and reputational risks; our difficulty or inability to promote and conduct our live events and/or other businesses if we do not comply with applicable regulations; our dependence on our intellectual property rights, our need to protect those rights, and the risks of our infringement of others’ intellectual property rights; the complexity of our rights agreements across distribution mechanisms and geographical areas; potential substantial liability in the event of accidents or injuries occurring during our physically demanding events including without limitation, claims alleging traumatic brain injury; large public events as well as travel to and from such events; our feature film business; our expansion into new or complementary businesses and/or strategic investments; our computer systems and online operations; privacy norms and regulations; a possible decline in general economic conditions and disruption in financial markets; our accounts receivable; our indebtedness including our convertible notes; litigation; our potential failure to meet market expectations for our financial performance, which could adversely affect our stock; Vincent K. McMahon exercises control over our affairs, and his interests may conflict with the holders of our Class A common stock; a substantial number of shares are eligible for sale by the McMahons and the sale, or the perception of possible sales, of those shares could lower our stock price; and the volatility of our Class A common stock. In addition, our dividend is dependent on a number of factors, including, among other things, our liquidity and historical and projected cash flow, strategic plan (including alternative uses of capital), our financial results and condition, contractual and legal restrictions on the payment of dividends (including under our revolving credit facility), general economic and competitive conditions and such other factors as our Board of Directors may consider relevant. Forward-looking statements made by the Company speak only as of the date made and are subject to change without any obligation on the part of the Company to update or revise them. Undue reliance should not be placed on these statements. For more information about risks and uncertainties associated with the Company’s business, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of the Company’s SEC filings, including, but not limited to, our annual report on Form 10-K and quarterly reports on Form 10-Q.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005523/en/

Media:

Joel Zietcer

WWE

+44 7768 043 874

[email protected]

Anna Chapman

Principality Stadium

+44 7734 900 229

[email protected]

Investors:

Seth Zaslow

203 352 1026

[email protected]

KEYWORDS: Europe United States United Kingdom North America Connecticut

INDUSTRY KEYWORDS: Entertainment Sports Other Entertainment General Entertainment Wrestling Events/Concerts

MEDIA:

Logo

Paysafe Expands Betsson Partnership Into US Sports-Betting Market

Global iGaming operator’s new Betsafe online sportsbook for Colorado has plugged into Paysafe for suite of traditional and alternative payment solutions

HOUSTON–(BUSINESS WIRE)–Paysafe (NYSE: PSFE), a leading specialized payments platform, today announced its expanded partnership with Betsson Group (STO: BETS-B), the international iGaming operator with multiple online sportsbook and casino brands, including Betsafe. Building on Paysafe’s longstanding payments support for Betsson globally, the company is now providing a range of traditional and alternative payment solutions to the new Betsafe online sportsbook for Colorado.

The extension of Betsson and Paysafe’s payments partnership to the U.S., starting in Colorado, is the latest phase of a partnership that dates back 15 years. Since 2007, Betsson brands have been offering their European players the paysafecard online cash, or eCash, solution, including in major markets such as Sweden, Germany, Italy, Spain, Denmark, and Greece. In tandem, Paysafe’s Skrill and NETELLER digital wallets are payment methods for Betsson iGaming brands in 60+ global markets.

Now, with Betsson’s recent launch of its Betsafe mobile sportsbook for Colorado, Paysafe is facilitating Centennial State players’ online credit and debit card deposits. Whether a sports bettor wants to wager on U.S. sports league games or international sports, their card deposit to fund their Betsafe account will be processed seamlessly through Paysafe’s best-in-breed payment gateway.

The Paysafe integration also sees Betsafe able to offer players a comprehensive selection of alternative payment methods (APMs). Colorado sports bettors will be able to use Paysafe’s Skrill USA digital wallet, which underwent a major product upgrade in Q4 2021, to instantly make deposits and receive payouts of their winnings. Alternatively, cash-focused sports bettors will be able to use either of Paysafe’s eCash solutions, paysafecard or Paysafecash. to fund their Betsafe accounts, with both APMs available at thousands of U.S. in-store retailers in Colorado and across the wider U.S.

Zak Cutler, CEO of North America iGaming at Paysafe, said: “We’re delighted to support our longstanding partner Betsson Group’s expansion into the U.S. sports-betting and iGaming space with their Betsafe brand. We have a proven track record facilitating payments for Betsson brands and their players in multiple European and global markets, and we’re confident that we’ll play an equally important customer acquisition and retention role for the operator in Colorado and beyond.”

Marina Bogard, Managing Director U.S. for Betsson Group, commented: “At Betsson, the customer is at the core of everything we do. We aim to make the entire journey on our brands as smooth and convenient as possible, including their deposit and payout experiences. As they have done in other markets, we are confident that Paysafe’s payment solutions will be able to support us with all our needs to achieve our goals.”

Paysafe is exhibiting at Stand N3-220 of the ICE London conference from April 12^th to 14^th, 2022.

About Paysafe Limited

Paysafe Limited (“Paysafe”) (NYSE: PSFE) (PSFE.WS) is a leading specialized payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through industry-leading capabilities in payment processing, digital wallet, and online cash solutions. With over 20 years of online payment experience, an annualized transactional volume of over U.S. $120 billion in 2021, and approximately 3,500 employees located in 10+ countries, Paysafe connects businesses and consumers across 100 payment types in over 40 currencies around the world. Delivered through an integrated platform, Paysafe solutions are geared toward mobile-initiated transactions, real-time analytics and the convergence between brick-and-mortar and online payments. Further information is available at www.paysafe.com.

About Paysafe iGaming

Paysafe brings over two decades of specialized payments experience supporting the global iGaming and sports-betting sectors and provides operators with a comprehensive suite of traditional and alternative payment methods through a single, streamlined API integration. Paysafe is also a leader in digital and affiliate marketing technology and services for iGaming operators through its Income Access business unit.

Since the opening-up of the U.S. iGaming market in May 2018, Paysafe has consistently stated its ambitions to be the payments leader in the fast-growing sector, building on its leadership in Canada and Europe. As of April 12^th, 2022, the company supports 75% of operators in the country with payments or marketing solutions across 21 jurisdictions. In Canada, Paysafe also has a leading position and partners with the majority of regulated iLottery and gaming brands.

About Betsson Group

With 20 brands, including Betsafe, Betsson, NordicBet and CasinoEuro, offering Sportsbook, Casino, and other games, Betsson Group is one of the world’s largest gaming groups, at the heart of entertainment for close to six decades. The company’s vision is to provide the best customer experience in the industry – listening to, and learning from, its customers, and then exceeding their expectations. Betsson Group is wholly owned by Betsson AB – listed on Nasdaq Stockholm.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005498/en/

For further information, please contact:

Nick Say, Senior Manager of Communications, North America, Paysafe

T: +1-514-452-8747; E: [email protected]

KEYWORDS: Colorado New York Texas Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Technology Other Sports Casino/Gaming Sports Finance Entertainment Banking Professional Services Software Internet

MEDIA:

Logo

Skills Shortage Inspires New Mainframe Plans in Europe

Modernization and cloud migration are slowly gaining traction as enterprises see rising costs, growth limitations, ISG Provider Lens™ report says

LONDON–(BUSINESS WIRE)–
Spurred by rising costs and a scarcity of legacy skills, a small but growing number of European enterprises are modernizing their mainframe applications or migrating them to the cloud, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.

The 2022 ISG Provider Lens™ Mainframes – Services and Solutions report for Europe finds companies are under increasing pressure to re-evaluate their use of mainframes in the wake of pandemic-related disruptions and changing business requirements. Providers of mainframe migration tools and services in Europe have seen revenue grow an average of 20 percent in the past year, an ISG survey finds.

Enterprises are pursuing mainframe modernization despite projects taking longer than expected and, in some cases, not reaching completion, ISG says. Companies should expect a lengthy process of analyzing systems and developing a long-term migration strategy.

“Demand is high, but execution has been slow, and the number of projects is still small,” said Anna Medkouri, ISG partner, Technology Modernization, in Germany. “Large migration providers are reporting an average of 15 to 30 projects per year in Europe.”

Mainframe costs are rising due to a shortage of COBOL language skills in European countries to maintain and manage legacy systems, the report says. In addition, independent software vendors are taking advantage of mainframe dependency with expensive expert services.

The COVID-19 crisis exposed the limitations of mainframes when some government agencies in Europe could not scale their systems fast enough to respond to increased demand from their citizens, ISG says. This caused some small system disruptions, heightening interest in migrating mainframe applications to the cloud.

Enterprises across Europe are turning to multinational service providers with the increasingly rare skills needed for large mainframe projects, the report says. Unlike for most IT services providers in Europe, language and culture do not give small players a local advantage.

“In this market, the language that matters is COBOL,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “Smaller companies compete by offering niche specializations and partnering with major providers.”

The report includes insights into other issues affecting enterprise mainframe strategies, including the role of hyperscale cloud providers and whether investments in modernizing COBOL are paying off.

The 2022 ISG Provider Lens™ Mainframes – Services and Solutions report for Europe evaluates the capabilities of 42 providers across five quadrants: Mainframe Modernization Services, Mainframe Application Modernization and Transformation Services, Mainframes as a Service (MFaaS), Mainframe Operations, and Mainframe Application Modernization Software.

The report names Atos, Capgemini, Infosys, Kyndryl and TCS as Leaders in three quadrants each and DXC Technology and Wipro as Leaders in two quadrants each. Advanced, Asysco, AWS (Blu Age), Cognizant, Google, HCL, Micro Focus, TmaxSoft and T-Systems are named as Leaders in one quadrant each.

In addition, Cognizant, Fujitsu, HCL, Heirloom Computing and TCS are named as Rising Stars – companies with a “promising portfolio” and “high future potential” by ISG’s definition – in one quadrant each.

Customized versions of the report are available from Google, Freesoft, Infosys and Kyndryl.

The 2022 ISG Provider Lens™ Mainframes – Services and Solutions report for Europe is available to subscribers or for one-time purchase on this webpage.

About ISG Provider Lens™ Research

The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG’s global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG’s enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.

A companion research series, the ISG Provider Lens Archetype reports, offer a first-of-its-kind evaluation of providers from the perspective of specific buyer types.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 800 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005332/en/

Press:

Will Thoretz, ISG

+1 203 517 3119

[email protected]

Kate Hartley, Carrot Communications for ISG

+44 (0)20 3457 6403

[email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Software Networks Internet Hardware Consulting Data Management Professional Services Technology

MEDIA:

Logo

Celonis and Accenture to Accelerate Digital Transformation for MANN+HUMMEL

Filtration leader selects Celonis and Accenture to further strengthen operational excellence and accelerate company-wide transformation into a data-driven enterprise

LUDWIGSBURG, Munich & NEW YORK–(BUSINESS WIRE)–Celonis and Accenture (NYSE: ACN) are teaming up to support MANN+HUMMEL, a global filtration solutions provider, to accelerate its company-wide digital transformation and become a data-driven enterprise. By leveraging intelligent insights and actions, MANN+HUMMEL will improve and optimize its processes to increase operational excellence and become even more customer-centric.

Accenture has supported MANN+HUMMEL’s data-driven enterprise journey since 2019. Together with global execution management leader Celonis, Accenture will foster the firm’s process excellence capabilities by helping to roll out Celonis’ Execution Management System across MANN+HUMMEL in a multi-year program.

With this strategic collaboration, MANN+HUMMEL will gain new levels of transparency and an objective, fact-based understanding of how its core business processes really run. This will enable MANN+HUMMEL to identify performance barriers in real-time and take automated action to remove inefficiencies and improve processes. Insights from the initial stages of deployment have already created process standardization and optimization in the areas of supply, distribution and production. This will be expanded on in the coming months across materials, planning and logistics, to improve cycle times and productivity, reduce rework, optimize inventory, increase automation and streamline global execution.

Emese Weissenbacher, executive vice president and chief financial officer at MANN+HUMMEL, said: “Our efforts and investments in standardization are all targeted towards being able to stay a step ahead of customers’ needs. Deploying Celonis market-leading process mining and execution management capabilities enables us to drive more intelligent, data-driven insights, measures and decisions. I am convinced with this transformation we can take our business processes to the next level and create an agile platform for continuous improvement.”

S/4HANA^® Migration – Minimizing Project Risks

Jean-Marc Erieau, program lead with MANN+HUMMEL, is responsible for steering the strategic program, and together with Accenture, will drive forward the change management and governance during the Celonis rollout. Celonis will help accelerate MANN+HUMMEL’s migration to SAP S/4HANA® and provide support before, during, and after the migration. By leveraging Celonis, MANN+HUMMEL already enjoys increased process standardization, reduced manual effort, mitigated project risks and minimized business disruption and is therefore well prepared for the SAP S/4HANA migration.

Thomas Rinn, global Industrial sector lead for Accenture said: “Building on the strong foundation we already established, rolling out Celonis is the next logical step at the right time for MANN+HUMMEL. With process mining and execution management, we will help MANN+HUMMEL achieve operational excellence, which will strengthen the firm’s position as a digital leader in the industry and help it achieve new business value for the company, its employees and customers.”

Celonis Center of Excellence accelerates transformation

Accenture and Celonis will also support MANN+HUMMEL in the establishment of a Celonis Center of Excellence (CoE) that will bring together all relevant experts to ensure a synchronized approach and efficient planning and implementation. The CoE will combine partner enablement support, professional services and value advisory for customers, as well as trained solution engineering and customer support teams to provide around-the-clock expertise and innovation.

“We are proud to be part of MANN+HUMMEL’s journey to transform into a data-driven enterprise and establish a sustainable operating model,” said Bastian Nominacher, Celonis co-founder and co-CEO. “With our shared value-based approach, we have accelerated the MANN+HUMMEL transformation journey in just a matter of weeks, and created the foundation to bolster their standardization roadmap, which will enable MANN+HUMMEL to deliver bold, company-wide transformation. We are supporting each phase of MANN+HUMMEL’s SAP S/4HANA migration, including reducing costly risks and roadblocks with intelligent data-driven insights, smoothing user adoption, and achieving key business outcomes at every stage of the rollout.”

About MANN+HUMMEL

MANN+HUMMEL is a leading global company in filtration technology. Under its two business units Transportation and Life Sciences & Environment, the Ludwigsburg-based Group develops intelligent solutions that enable cleaner mobility, cleaner air and cleaner water. Thus, the company makes an important contribution to a clean earth and the sustainable use of limited resources. In 2020, over 21,000 employees at more than 80 locations generated a turnover of EUR 3.8 billion.

Among the solutions are filter media and simulation technologies, liquid filters, air filtration and intake systems for various mobility and industrial applications, and membrane technologies for municipal and industrial water and wastewater treatment and use in sensitive process applications such as food manufacturing or biotechnology. Furthermore, the family-owned company founded in 1941 offers air and molecular filtration technologies for building filtration as well as for industrial applications and cleanrooms. These are used, for example, in power generation, microelectronics or operating rooms. Stationary and mobile air purifiers for indoor, semi-open spaces and outdoor areas complete the holistic approach to clean air. Depending on the area of application, they filter viruses, free allergens, bacteria or fine dust and nitrogen oxides from the ambient air.

You can find further information on MANN+HUMMEL at https://www.mann-hummel.com/

About Celonis

Celonis helps organizations to execute on their data. Powered by its market-leading process mining core, the Celonis Execution Management System provides a set of applications, a developer studio and platform capabilities for business executives and users to eliminate billions in corporate inefficiencies, provide better customer experience and reduce carbon emissions. Celonis has thousands of global customers and is headquartered in Munich, Germany and New York City, USA with 16 offices worldwide.

© 2021 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.

About Accenture

Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 699,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at accenture.com.

SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005257/en/

Andreas Wallbillich

MANN+HUMMEL

[email protected]

Isabell Horvath

Celonis

[email protected]

Youssef Zauaghi

Accenture

+49 1755766458

[email protected]

Hannah Unkefer

Accenture

Intelligent Platform & Ecosystem Media Relations

+1 206 839 2172

[email protected]

KEYWORDS: New York Germany Europe United States North America

INDUSTRY KEYWORDS: Software Technology Networks Data Management

MEDIA:

Posted on April 12, 2022 3:04 am

Mainz Biomed Announces First Quarter 2022 Results

BERKELEY, Calif. and MAINZ, Germany, April 12, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today operational results for the first quarter ended March 31, 2022.

Key Highlights

• Continued to ramp up EU commercial activities for ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer
• Acquired portfolio of novel mRNA biomarkers to potentially upgrade ColoAlert’s technical profile to achieve “gold standard” status for CRC at-home testing
• Commenced international clinical study (ColoFuture) to evaluate integration of these biomarkers into ColoAlert
• Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial
• Formally initiated ColoAlert’s U.S. medical reimbursement process with the Centers for Medicare Services (CMS)
• Executed a $25.8 million public follow-on offering
• Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization

“This past quarter has proven to be an excellent period of progress across commercial, corporate and product development fronts,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The entire Mainz team is excited by the rapid growth achieved to date and remains steadfast in our conviction to advance an ambitious yet balanced strategy to maximize ColoAlert’s potential in the marketplace, and to build our oncology-focused diagnostic franchise via a unique commercial model and robust technical approach to product development.”

Commercial Update: ColoAlert marketed across Europe via unique business model

During the quarter, Mainz continued its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. Under the standard terms of all partnerships, Mainz is providing ColoAlert to the respective labs, including co-branding with key accounts, whereby each facility purchases Mainz’s customized polymerase chain reaction (PCR) assay kits on an on-demand basis and provides to their respective network of physicians and patients a comprehensive solution for advanced CRC protection. During the first quarter (February 2022), Mainz announced a partnership with Labor MVZ Dr. Stein + Kollegen (“Laboratory Mönchengladbach”), one of the largest diagnostics laboratories in the North Rhine-Westphalia region of Germany. The Lab services over 2,500 physicians, processing over five million samples in total annually and screening approximately 1,000 patients per week specifically for CRC. With the addition of Laboratory Mönchengladbach, Mainz now has four core partnerships including GANZIMMUN Diagnostics AG, one of Europe’s leading laboratories for preventive and complementary medicine which processes approximately 5,500 laboratory orders daily.

ColoAlert R&D Update: ColoFuture study evaluating acquired mRNA biomarkers

In February 2022, Mainz initiated a clinical study (ColoFuture) to evaluate a portfolio of five gene expression biomarkers acquired from Socpra Sciences Santé Et Humaines S.E.C. in January 2022. The results from a published study in the peer review journal MDPI (March 11, 2021) demonstrated that these specific biomarkers have a high degree of effectiveness in detecting CRC lesions including advanced adenomas (“AA”), a type of pre-cancerous polyp often attributed to this deadly disease. As such, the ColoFuture study will determine if the biomarkers enhance ColoAlert’s technical profile to extend its capability to include the identification of advanced adenomas (AA) while increasing ColoAlert’s rates of diagnostic sensitivity and specificity. If the data results from ColoFuture are successful, ColoAlert will be positioned as the most robust and accurate at-home diagnostic screening test on the market, as it will not only detect cancerous polyps with a high degree of accuracy but has the potential to prevent CRC through early detection of precancerous adenomas.

To ensure optimal study execution, the Company announced during the first quarter strategic partnerships with Sentinel Diagnostics and Alcedis GmbH. Sentinel Diagnostics is a global leader in the development and production of in vitro diagnostics (IVD), and Alcedis GmbH is a full-service state-of-the-art contract research organization (CRO) providing clinical trial management for biotechnology and medical device companies across the globe. With Sentinel, Mainz has been granted access to the SENTiFIT® 270 Analyzer, Sentinel’s leading automated Fecal Immunochemical Test (FIT) processing system. An essential component of ColoAlert is the utilization of a FIT which provides a complete review of blood in the stool, a condition often associated with cancerous polyps and colorectal carcinoma. It is the combination of ColoAlert and FIT results that provide the diagnostic outcome. This partnership enables Mainz to transition from deploying a manual FIT processing methodology to a state-of-the-art automated system for potential future use in the EU commercial setting, and in the Company’s forthcoming U.S. clinical trial. Alcedis is providing Mainz with the full range of services and responsibilities associated with executing ColoFuture, including patient recruitment, overseeing study protocol compliance, and the documentation and reporting of patient results.

The ColoFuture study will enroll over 600 patients in the age range of 40-85 at two participating centers in Norway and two in Germany. The Company expects to complete enrollment during the second half of 2022 and is targeting reporting study results in early 2023. Additionally, data results from ColoFuture will impact ColoAlert’s profile for FDA submission.

ColoAlert’s U.S. Regulatory Approval Update: Pre-submission for pivotal trial design receives feedback from the FDA and medical reimbursement process launched with CMS

In March 2022, Mainz announced that it received supportive feedback from the U.S. Food & Drug Administration on its pre-submission package for ColoAlert. The Company will continue working with its clinical team to finalize the study’s protocols and prepare for the multi-center study which is on track to commence in late 2022. As part of the Company’s activities to prepare for the initiation of the pivotal trial, Mainz also announced the formal commencement of its medical reimbursement process for ColoAlert by scheduling an initial meeting with the Centers for Medicare and Medicaid Services (CMS) which is set to take place in April 2022. CMS is a federal agency in the U.S. Department of Health and Human Services (HHS) that administers the Medicare program and works in partnership with state governments to administer Medicaid, the Children’s Health Insurance Program (CHIP), and health insurance portability standards.

Corporate Update: Successful follow-on offering, key appointments to management team & Strategic Advisory Board.

In January 2022, the Company announced a $25.8 million public follow-on offering consisting of 1,725,000 of ordinary shares priced at $15.00 per share. Boustead Securities, LLC acted as the sole underwriter for the transaction. The Company plans to file its Report on Form 20-F, including audited financial statements for 2021, with the U.S. Securities and Exchange Commission in April 2022.

Throughout the first quarter, the Company continued to bolster its leadership team highlighted by the appointments of former Abbott Diagnostics executive Steve Quinn as Vice President of Business Development (January) along with the two high profile additions to Mainz’s Strategic Advisory Board. In January, Dr. Michele Pedrocchi joined the SAB followed by the February appointment of Dr. Rainer Metzger. Dr. Pedrocchi is the former Head of Roche Diagnostics Business Development and brings to the SAB over 25 years of international experience at Roche spanning in vitro diagnostics, digital health, and personalized medicine. Dr. Metzger is a Former Danaher, Roche and Qiagen Executive with over 25 years of experience within the pharmaceutical and diagnostic industries.

About ColoAlert

ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the European Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.
*Dollinger MM et al. (2018)

About Colorectal Cancer

Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late-stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimates that in 2021 there will be approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently, there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US-based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.

About Mainz Biomed N.V.

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

For more information, please visit www.mainzbiomed.com

For media enquiries, please contact

[email protected]

For investor enquiries, please contact

[email protected]

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its registration statement on Form F-1 filed on January 21, 2022. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Posted on April 12, 2022 2:32 am

Autoliv launches multi-year commitment to support the UN Road Safety Fund

PR Newswire

STOCKHOLM and NEW YORK and Usa, April 12, 2022 /PRNewswire/ — Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety systems, is supporting the United Nations Road Safety Fund (UNRSF) to strengthen insights into road safety challenges, contribute to safer mobility and help deliver Autoliv’s goal of saving 100,000 lives a year.

By exchanging valuable insights, knowledge, and data, Autoliv and UNRSF will actively support the Global Plan for the Second Decade of Action 2021-2030, which seeks to prevent at least 50% of road traffic deaths and injuries by 2030.

Road traffic crashes claim 1.35 million lives every year and are the leading cause of death among children and young adults. More than 90 per cent of road traffic fatalities take place in developing countries. Autoliv’s support of UNRSF is an important step to further democratize road safety and increase awareness and availability of life-saving products where it is most needed.

Shaping the future of mobility in a safer and more sustainable way  

Autoliv’s vision of Saving More Lives directly supports UN Sustainable Development Goal (SDG) number three, which aspires to ensure good health and well-being for all, with one of its targets focused on halving global deaths and injuries from road traffic crashes.

“Cross-sector collaboration is key if the world is to advance its positions on the Sustainable Development Goals. Supporting the UNRSF is a way for Autoliv to share our expertise while gaining additional insights into the main road safety challenges facing the world today. Through our core business of life-saving products, we have an important role to play. Saving More Lives is an integral part of our sustainability agenda, and our aim is to save 100,000 lives a year”, says Mikael Bratt, CEO and President, Autoliv.

Cross-sector collaborations required to reach global sustainability goals

“As a member of the multi-stakeholder

UNRSF Platforms of Engagement

, Autoliv directly supports UNRSF thinking on high-impact road safety projects. With its financial contribution, Autoliv is also directly supporting UNRSF project operations in low- and middle-income countries. It is this type of multi-pronged engagement from the private sector which will leapfrog the global community towards achieving the SDGs on safe, sustainable and inclusive mobility for all” says Nneka Henry, Head of the UNRSF Secretariat.

Autoliv’s commitment to support the UNRSF will directly result in road safety interventions in low- and middle-income countries ranging from better vehicle standards and road infrastructure design to effective systems to improve road user behavior and emergency post-crash response.

Inquiries: 

Media: Gabriella Ekelund, Tel +46 (70) 612 64 24
Investors & Analysts: Anders Trapp, Tel +46 (0)8 587 206 71
Investors & Analysts: Henrik Kaar, Tel +46 (0)8 587 206 14

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/autoliv/r/autoliv-launches-multi-year-commitment-to-support-the-un-road-safety-fund,c3542390

The following files are available for download:

https://mb.cision.com/Main/751/3542390/1562108.pdf	Press release as PDF
https://news.cision.com/autoliv/i/more-saved-04-2,c3036081	More Saved 04 2